GLUD1 and glioma: In order to avoid the overfitting of prognostic signature, we performed LASSO regression analysis on these RBPs next by 10-round cross-validation, and found 19 candidates that were closely associated with the prognosis of glioma patients, including: MSN, STEAP3, IGF2BP3, NSUN6, CTSC, GNS, HMGN5, RANBP17, SMC4, DUSP9, GLUD1, PTTG1, MCAM, KHDRBS2, GGH, ST6GALNAC1, TET1, KLB, ZNF483 (Figure 4A,B).